Ilant Health is a technology company.
Ilant Health has raised $100K across 1 funding round.
Ilant Health has raised $100K in total across 1 funding round.
Ilant Health is a technology-enabled healthcare company specializing in obesity and cardiometabolic treatment, offering a comprehensive, value-based care model that integrates obesity medicine, nutrition, psychology, exercise physiology, and medication management to improve outcomes and reduce costs for employers and health plans.[1][2][3] It serves individuals with obesity—particularly those with high disease burden—through personalized, data-driven pathways that address medical, behavioral, and lifestyle needs, solving the problems of fragmented care, stigma, data invisibility in claims (where only 5-10% reflect obesity despite 40-50% prevalence), and ineffective one-size-fits-all solutions.[1][2] Founded in 2022 and based in New York, the seed-stage company has raised $5.55M, including a $2.5M round about a year ago, and reports over 2x ROI in under two years via reduced recidivism, chronic disease management, and equity-focused access for underserved communities.[1][2]
Ilant Health was founded in 2022 by Elina Onitskansky, who serves as CEO and drives the company's vision for personalized obesity care.[1][3] Onitskansky identified key gaps in traditional healthcare, such as systemic neglect due to poor data visibility and generic treatments that fail to meet patients' unique needs, prompting her to build a holistic platform leveraging technology, analytics, and evidence-based interventions.[1] Early traction came from its value-based model targeting employers and payers, with recent expansions like direct contracting for obesity management medicines announced in late 2025, enhancing access and transparency.[3] This evolution reflects a response to rising obesity prevalence and demand for sustainable, cost-effective solutions.[1][2]
Ilant Health stands out through these key strengths:
Ilant Health rides the wave of value-based care in digital health, capitalizing on surging demand for obesity treatments amid GLP-1 drugs like semaglutide and rising cardiometabolic disease burdens, where traditional fee-for-service models fail due to high recidivism and inequities.[1][2][3] Timing is ideal post-2022 founding, aligning with employer priorities for cost control (obesity drives massive claims gaps) and post-pandemic health focus, amplified by 2025 direct contracting innovations for transparent medication access.[3] Market forces like analytics advancements and payer shifts favor its population-health model, which influences the ecosystem by proving scalable personalization reduces systemic neglect and sets benchmarks for tech-enabled chronic care platforms.[1][2]
Ilant Health is poised to scale its seed-stage momentum through deeper employer partnerships and expanded direct medicine access, potentially capturing more of the underserved obesity market with its proven ROI and analytics edge.[1][3] Trends like AI-driven personalization, hybrid virtual care, and payer incentives for outcomes will accelerate growth, evolving its influence from niche provider to ecosystem leader in cardiometabolic health. As obesity crises intensify, Ilant's rejection of generic fixes positions it to redefine accessible, stigma-free treatment at scale.[1][2]
Ilant Health has raised $100K in total across 1 funding round.
Ilant Health's investors include 3 Points Rising Ventures, Innovation Works.
Ilant Health has raised $100K across 1 funding round. Most recently, it raised $100K Seed in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $100K Seed | 3 Points Rising Ventures, Innovation Works |